Optimization of Anti-IL17 Antibody Therapy by Associating Fiber Supplementation to Correct Treatment-aggravated Gut Dysbiosis in Axial Spondyloarthritis - RESPOND-IL17

IDRCB : 2022-A00135-38

Fiber is the main source of energy for colonic bacteria and its consumption favorably modifies the composition of the microbiota in only a few days. Their fermentation in the colon releases short-chain fatty acids (SCFAs). Clostridiales contain many strains producing SCFAs. These SCFAs can restore the intestinal barrier and promote certain anti-inflammatory cells, including regulatory T cells (Tregs), which are essential to the mechanisms in tolerance of the self. Fibers could therefore correct the intestinal abnormalities present in patients with axial spondyloarthritis (AxSpA) and aggravated by anti-IL-17 drugs and thus improve the therapeutic response to these treatments. The hypothesis is that dietary fiber will correct the dysbiosis in AxSpA patients and increase the release of SCFAs, which favorably modulate the immune response and improve AxSpA.

2023-10-02

2026-12-01

2026-12-01

Recruiting

36

Inclusion criteria: * Patients with spondyloarthritis meeting the ASAS criteria * Patient considered by the treating rheumatologist for anti-IL-17 biomedication * Patients aged between 18 and 90 years of age * Patients who are affiliated to a French social security system or beneficiaries of such a system * Patients with no desire to become pregnant during the study period (Effective contraception for women of childbearing age during the study period (surgical sterilization, hormonal contraceptives, barrier method, intrauterine device)) Exclusion Criteria: * Lack of written informed consent after a time of reflection * Patients participating in other therapeutic research or having participated in research for which the exclusion period has not ended * Patient under court protection, guardianship or curatorship. * Patient unable to give consent. * Pregnant or breastfeeding woman * Patients with digestive disorders for which a chronic inflammatory bowel disease has not been excluded * Patients with fructose intolerance or glucose or galactose malabsorption * Patients with known intolerance to inulin or maltodextrin

{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Multicenter, double-blind, prospective, randomized controlled study', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'maskingDescription': 'All treatments will be numbered. The treatment number will be assigned according to the randomization list. All participants (patient/evaluator/etc.) will be blinded to the treatment administered. Only the hospital pharmacy will know the assigned treatment and will guarantee the blinding.', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 36, 'type': 'ESTIMATED'}}

2023-10-04